Meiji Seika Pharma said on August 26 that it has obtained Japanese regulatory approval for an updated version of its self-amplifying mRNA COVID-19 vaccine Kostaive targeting the Omicron NB.1.8.1 subvariant. The partial change approval, granted on August 25, covers Kostaive…
To read the full story
Related Article
- Japan Picks 5 COVID Vaccines for NIP Use from October
September 3, 2026
- Japan Selects JN.1 Substrains for COVID Vaccines in 2026-2027 Season
May 27, 2026
BUSINESS
- Sanofi Japan Targets AI Fluency across Workforce by End-2027
September 16, 2026
- Mounjaro Label Updated with PIII CV Data Showing Noninferiority
September 16, 2026
- JCR Outside Director Fauchet Steps Down
September 16, 2026
- MSD Files Oral PCSK9 Inhibitor Enlicitide in Japan
September 15, 2026
- Takeda’s Zasocitinib Gets FDA Priority Review in Plaque Psoriasis
September 15, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





